These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1281566)

  • 1. Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor.
    Parenteau GL; Dirbas FM; Garmestani K; Brechbiel MW; Bukowski MA; Goldman CK; Clark R; Gansow OA; Waldmann TA
    Transplantation; 1992 Dec; 54(6):963-8. PubMed ID: 1281566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation.
    Cooper MM; Robbins RC; Goldman CK; Mirzadeh S; Brechbiel MW; Stone CD; Gansow OA; Clark RE; Waldmann TA
    Transplantation; 1990 Nov; 50(5):760-5. PubMed ID: 2238051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.
    Brown PS; Parenteau GL; Dirbas FM; Garsia RJ; Goldman CK; Bukowski MA; Junghans RP; Queen C; Hakimi J; Benjamin WR
    Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2663-7. PubMed ID: 2011577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival.
    Tinubu SA; Hakimi J; Kondas JA; Bailon P; Familletti PC; Spence C; Crittenden MD; Parenteau GL; Dirbas FM; Tsudo M
    J Immunol; 1994 Nov; 153(9):4330-8. PubMed ID: 7930631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody.
    Reed MH; Shapiro ME; Strom TB; Milford EL; Carpenter CB; Weinberg DS; Reimann KA; Letvin NL; Waldmann TA; Kirkman RL
    Transplantation; 1989 Jan; 47(1):55-9. PubMed ID: 2643232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac.
    Waldmann TA; White JD; Carrasquillo JA; Reynolds JC; Paik CH; Gansow OA; Brechbiel MW; Jaffe ES; Fleisher TA; Goldman CK; Top LE; Bamford R; Zaknoen E; Roessler E; Kasten-Sportes C; England R; Litou H; Johnson JA; Jackson-White T; Manns A; Hanchard B; Junghans RP; Nelson DL
    Blood; 1995 Dec; 86(11):4063-75. PubMed ID: 7492762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma.
    Waldmann TA
    Important Adv Oncol; 1994; ():131-41. PubMed ID: 8206486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At.
    Wesley JN; McGee EC; Garmestani K; Brechbiel MW; Yordanov AT; Wu C; Gansow OA; Eckelman WC; Bacher JD; Flynn M; Goldman CK; MacLin M; Schwartz UP; Jackson-White T; Phillip CM; Decker J; Waldmann TA
    Nucl Med Biol; 2004 Apr; 31(3):357-64. PubMed ID: 15028248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
    Waldmann TA; Goldman CK
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloablative irradiation and granulocyte colony-stimulating factor prolong the survival of chimeric limb allografts in a rodent model.
    Muramatsu K; Kato H; Yoshida Y; Moriya A; Taguchi T
    Plast Reconstr Surg; 2010 Jul; 126(1):53-60. PubMed ID: 20595856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1992 Stohlman Memorial Lecture: targeting the IL-2 receptor.
    Waldmann TA
    Leukemia; 1993 Aug; 7 Suppl 2():S151-6. PubMed ID: 8361223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.
    Kirkman RL; Shapiro ME; Carpenter CB; McKay DB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
    Transplantation; 1991 Jan; 51(1):107-13. PubMed ID: 1846250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A clinical study of haploidentical and G-CSF primed bone marrow transplantation by using CD25 for aGVHD prophylaxis].
    Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Oct; 10(5):447-51. PubMed ID: 12513746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Schmidberger H; Buchsbaum DJ; Everson P; Snover DC; Blazar BR
    Cancer Res; 1991 Apr; 51(7):1891-7. PubMed ID: 2004372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant interleukin 3 induces interleukin 2 receptor expression on early myeloid cells in normal human bone marrow.
    Gazzola MV; Collins NH; Tafuri A; Keever CA
    Exp Hematol; 1992 Feb; 20(2):201-8. PubMed ID: 1371965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression.
    Kitayama T; Hayamizu K; Egi H; Ohmori I; Yoshimitsu M; Asahara T
    Transplantation; 2003 Feb; 75(4):553-6. PubMed ID: 12605126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolongation of allograft survival by administration of mAb specific for the three subunits of IL-2 receptor.
    Yasuda K; Nemoto T; Ohashi Y; Satomi S; Murata K; Ishii N; Takeshita T; Sugamura K
    Int Immunol; 1998 May; 10(5):561-7. PubMed ID: 9645604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.